Literature DB >> 12045368

Therapeutic considerations in the treatment of obesity hypertension.

M R Wofford1, M M Davis, K G Harkins, D S King, S B Wyatt, D W Jones.   

Abstract

Obesity, now recognized as an independent risk factor for cardiovascular disease, is closely associated with hypertension. Complex mechanisms link increasing body weight with increasing blood pressure. Treatment of the obese patient with hypertension requires consideration of physiologic changes related to obesity hypertension. Lifestyle modification, including weight reduction and increased physical activity, can directly influence blood pressure levels and improve blood pressure control in obese, hypertensive patients. Clinical trials are needed to determine the most effective antihypertensive drugs for the obese, hypertensive patient. Antiobesity drugs offer viable adjunctive pharmacotherapy for obesity hypertension, but additional long-term studies are needed to support their safety and efficacy. Copyright 2002 Le Jacq Communications, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12045368      PMCID: PMC8101864          DOI: 10.1111/j.1524-6175.2002.00502.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  44 in total

1.  Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X.

Authors:  G Reaven; K Segal; J Hauptman; M Boldrin; C Lucas
Journal:  Am J Cardiol       Date:  2001-04-01       Impact factor: 2.778

2.  Valvular heart disease associated with fenfluramine-phentermine.

Authors:  H M Connolly; J L Crary; M D McGoon; D D Hensrud; B S Edwards; W D Edwards; H V Schaff
Journal:  N Engl J Med       Date:  1997-08-28       Impact factor: 91.245

3.  The effect of weight loss intervention on antihypertensive medication requirements in the hypertension Optimal Treatment (HOT) study.

Authors:  D W Jones; M E Miller; M R Wofford; D C Anderson; M E Cameron; D L Willoughby; C T Adair; N S King
Journal:  Am J Hypertens       Date:  1999-12       Impact factor: 2.689

4.  Antihypertensive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects.

Authors:  M R Wofford; D C Anderson; C A Brown; D W Jones; M E Miller; J E Hall
Journal:  Am J Hypertens       Date:  2001-07       Impact factor: 2.689

5.  Body mass index and blood pressure in Korean men and women: the Korean National Blood Pressure Survey.

Authors:  D W Jones; J S Kim; M E Andrew; S J Kim; Y P Hong
Journal:  J Hypertens       Date:  1994-12       Impact factor: 4.844

6.  Hemodynamic consequences of obstructive sleep apnea.

Authors:  J W Weiss; S Remsburg; E Garpestad; J Ringler; D Sparrow; J A Parker
Journal:  Sleep       Date:  1996-06       Impact factor: 5.849

Review 7.  Cardiovascular actions of insulin: are they important in long-term blood pressure regulation?

Authors:  J E Hall; M W Brands; D H Zappe; M Alonso-Galicia
Journal:  Clin Exp Pharmacol Physiol       Date:  1995-10       Impact factor: 2.557

8.  Sympathetic activation in obese normotensive subjects.

Authors:  G Grassi; G Seravalle; B M Cattaneo; G B Bolla; A Lanfranchi; M Colombo; C Giannattasio; A Brunani; F Cavagnini; G Mancia
Journal:  Hypertension       Date:  1995-04       Impact factor: 10.190

Review 9.  Hyperinsulinemia: possible role in obesity-induced hypertension.

Authors:  L Landsberg
Journal:  Hypertension       Date:  1992-01       Impact factor: 10.190

10.  Weight-reducing effects of the plasma protein encoded by the obese gene.

Authors:  J L Halaas; K S Gajiwala; M Maffei; S L Cohen; B T Chait; D Rabinowitz; R L Lallone; S K Burley; J M Friedman
Journal:  Science       Date:  1995-07-28       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.